Total Payments
$7,718
2024 Payments
$6,706
Companies
8
Transactions
34
Medicare Patients
2,381
Medicare Billing
$290,090

Payment Breakdown by Category

Consulting$7,071 (91.6%)
Food & Beverage$646.73 (8.4%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $7,071 27 91.6%
Food and Beverage $646.73 7 8.4%

Top Paying Companies

Company Total Records Latest Year
Regeneron Pharmaceuticals, Inc. $3,853 5 $0 (2024)
Takeda Pharmaceuticals U.S.A., Inc. $2,732 22 $0 (2024)
Eli Lilly and Company $500.00 1 $0 (2018)
Janssen Biotech, Inc. $249.88 2 $0 (2024)
Ardelyx, Inc. $148.71 1 $0 (2023)
Regeneron Healthcare Solutions, Inc. $118.73 1 $0 (2023)
AbbVie Inc. $97.26 1 $0 (2023)
Laborie Medical Technologies Corp. $18.24 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $6,706 29 Regeneron Pharmaceuticals, Inc. ($3,853)
2023 $511.55 4 Ardelyx, Inc. ($148.71)
2018 $500.00 1 Eli Lilly and Company ($500.00)

All Payment Transactions

34 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
11/10/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $55.00 General
11/10/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $24.10 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $225.80 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $197.38 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $197.38 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $139.28 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $122.54 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $122.54 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $73.00 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $48.98 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $48.95 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $39.97 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $33.97 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $33.97 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $19.65 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $19.65 General
11/07/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $19.65 General
10/18/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $548.00 General
10/18/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $26.89 General
10/11/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $411.18 General
10/11/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $288.98 General
10/11/2024 Takeda Pharmaceuticals U.S.A., Inc. Consulting Fee Cash or cash equivalent $35.00 General
10/08/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Food and Beverage In-kind items and services $103.03 General
Category: Immunology
10/01/2024 Laborie Medical Technologies Corp. alpHaONE (Device) Food and Beverage Cash or cash equivalent $18.24 General
Category: Gastroenterology
09/19/2024 Regeneron Pharmaceuticals, Inc. DUPIXENT (Biological) Consulting Fee Cash or cash equivalent $2,094.00 General
Category: INFLAMMATION AND IMMUNOLOGY

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 12 508 552 $716,608 $62,027
2022 14 618 648 $786,696 $74,476
2021 16 663 742 $862,039 $82,927
2020 17 592 665 $624,727 $70,661
Total Patients
2,381
Total Services
2,607
Medicare Billing
$290,090
Procedure Codes
59

All Medicare Procedures & Services

59 procedure records from CMS Medicare Utilization — Page 2 of 3

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99231 Follow-up hospital inpatient care per day, typically 15 minutes Facility 2022 16 17 $2,907 $567.29 19.5%
99204 New patient outpatient visit, total time 45-59 minutes Office 2021 122 122 $132,370 $16,317 12.3%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 77 99 $84,942 $10,431 12.3%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 64 69 $61,410 $8,008 13.0%
43239 Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope Facility 2021 78 79 $132,799 $6,584 5.0%
45380 Biopsy of the large bowel using an endoscope (colonoscopy) Facility 2021 65 65 $147,745 $6,572 4.4%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 40 43 $41,280 $6,365 15.4%
45390 Removal of large bowel tissue using a flexible endoscope (colonoscopy) Facility 2021 21 21 $32,844 $5,941 18.1%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 46 69 $32,430 $4,282 13.2%
45385 Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare Facility 2021 21 21 $53,529 $3,533 6.6%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 15 15 $20,400 $2,945 14.4%
43235 Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope Facility 2021 27 27 $39,420 $2,695 6.8%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 12 14 $18,480 $2,421 13.1%
45378 Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk Facility 2021 14 14 $26,698 $2,191 8.2%
99231 Subsequent hospital inpatient care, typically 15 minutes per day Facility 2021 37 60 $10,260 $1,987 19.4%
43251 Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope using a mechanical snare Facility 2021 12 12 $25,320 $1,610 6.4%
99443 Physician telephone patient service, 21-30 minutes of medical discussion Office 2021 12 12 $2,112 $1,045 49.5%
99205 New patient office or other outpatient visit, typically 60 minutes Office 2020 91 91 $82,810 $15,060 18.2%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 69 88 $50,160 $7,732 15.4%
45380 Biopsy of large bowel using an endoscope Facility 2020 61 61 $131,333 $7,489 5.7%
99215 Established patient office or other outpatient, visit typically 40 minutes Office 2020 58 64 $40,960 $7,428 18.1%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2020 39 41 $24,395 $4,940 20.3%
43239 Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope Facility 2020 65 69 $108,675 $4,452 4.1%
45390 Removal of large bowel tissue using an endoscope Facility 2020 12 12 $17,880 $3,453 19.3%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 27 47 $14,805 $2,952 19.9%

About Dr. Guy Weiss, M.D

Dr. Guy Weiss, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2010. The National Provider Identifier (NPI) number assigned to this provider is 1598084030.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Guy Weiss, M.D has received a total of $7,718 in payments from pharmaceutical and medical device companies, with $6,706 received in 2024. These payments were reported across 34 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($7,071).

As a Medicare-enrolled provider, Weiss has provided services to 2,381 Medicare beneficiaries, totaling 2,607 services with total Medicare billing of $290,090. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.

Practice Information

Products in Payments

  • DUPIXENT (Biological) $3,972
  • IBSRELA (Drug) $148.71
  • STELARA (Biological) $146.85
  • TREMFYA (Drug) $103.03
  • RINVOQ (Biological) $97.26
  • alpHaONE (Device) $18.24

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Student in an Organized Health Care Education/Training Program Doctors in Buffalo